July, 17 2025 Thursday 13:33 Hrs
  • SENSEX :   82,435.59

  • Top commodity trading and broking companies in India-198.89( -0.24%) 17-Jul-2025
top-arrow-market
Sensex 82441.13 -193.35  (-0.23) 17-Jul-2025
Previous Day Close
82634.48
Today's High/Low
High Low
  •  
  •  
82757.09 82403.29

Company News Details

Zydus Lifesciences Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532321
INE010B01027
210.5884278
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ZYDUSLIFE
16.88
97463.82
EPS(TTM)
Face Value()
Div & Yield %
57.39
1
1.14
 

Zydus Lifesciences Ltd
Zydus Lifesciences gets USFDA Nod for Celecoxib Capsules
Jul 15,2025
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body. It is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain. It is also used to treat juvenile rheumatoid arthritis in children who are at least 2 years old. Celecoxib capsules will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.

According to IQVIA MAT data (May 2025), Celecoxib Capsules recorded annual sales of approximately USD 122.6 million in the U.S. market.

With this approval, Zydus has now secured a total of 428 final approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since it began its U.S. regulatory filing process in FY 2003–04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company’s consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24.

The counter shed 0.14% to Rs 967.15 on the BSE.

Top
Attention Investor:
Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.